Autophagy-dependent survival of mutant B-Raf melanoma cells selected for resistance to apoptosis induced by inhibitors against oncogenic B-Raf

Biomolecules and Therapeutics

Volumn 21, Issue 2, 2013, Pages 114-120

  Ahn, Jun Ho ^a   Lee, Michael ^a  

^a SolarLight Ltd   (South Korea)

Author keywords

Autophagy; B Raf inhibitor; Cell cycle arrest; Drug resistance; Melanoma; UI 152

Indexed keywords

3 METHYLADENINE; B RAF KINASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; UI 152; UNCLASSIFIED DRUG; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CELL CLONE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG SENSITIZATION; HUMAN; HUMAN CELL; IC 50; MELANOMA CELL; MUTANT; PROTEIN EXPRESSION;

EID: 84875798054     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2013.012     Document Type: Article

References (34)

1. Ahn, J.-H., Ahn, S. K. and Lee, M. (2012) The role of autophagy in cytotoxicity induced by new oncogenic B-Raf inhibitor UI-152 in v-Ha-ras transformed fibroblasts. Biochem. Biophys. Res. Commun. 417, 857-863.
2. Ahn, J.-H., Eum, K.-H. and Lee, M. (2010) Spry2 does not directly modulate Raf-1 kinase activity in v-Ha-ras-transformed NIH 3T3 fibroblasts. BMB Rep. 43, 205-211.
3. Ahn, J.-H. and Lee, M. (2011) Suppression of autophagy sensitizes multidrug resistant cells towards Src tyrosine kinase specific inhibitor PP2. Cancer Lett. 310, 188-197.
4. Blagosklonny, M. V. (2007) Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle 6, 70-74.
5. Cagnol, S. and Chambard, J. C. (2010) ERK and cell death: mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence. FEBS J. 277, 2-21.
6. Corcelle, E., Nebout, M., Bekri, S., Gauthier, N., Hofman, P., Poujeol, P., Fénichel, P. and Mograbi, B. (2006) Disruption of autophagy at the maturation step by the carcinogen lindane is associated with the sustained mitogen-activated protein kinase/extracellular signal-regulated kinase activity. Cancer Res. 66, 6861-6870.
7. Dhomen, N. and Marais, R. (2009) BRAF signaling and targeted therapies in melanoma. Hematol. Oncol. Clin. North Am. 23, 529-545.
8. Eisen, T., Ahmad, T., Flaherty, K. T., Gore, M., Kaye, S., Marais, R., Gibbens, I., Hackett, S., James, M., Schuchter, L. M., Nathanson, K. L., Xia, C., Simantov, R., Schwartz, B., Poulin-Costello, M., O'Dwyer, P. J. and Ratain, M. J. (2006) Sorafenib in advanced melanoma: A Phase II randomised discontinuation trial analysis. Br. J. Cancer 95, 581-586.
9. Engelman, J. A. and Jänne, P. A. (2008) Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 14, 2895-2899.
10. Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K. and Chapman, P. B. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 908-819.
11. Gottesman, M. M. (2002) Mechanisms of cancer drug resistanace. Annu. Rev. Med. 53, 615-627.
12. Jiang, C. C., Lai, F., Thorne, R. F., Yang, F., Liu, H., Hersey, P. and Zhang, X. D. (2011) MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin. Cancer Res. 17, 721-730.
13. Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., Caponigro, G., Hieronymus, H., Murray, R. R., Salehi-Ashtiani, K., Hill, D. E., Vidal, M., Zhao, J. J., Yang, X., Alkan, O., Kim, S., Harris, J. L., Wilson, C. J., Myer, V. E., Finan, P. M., Root, D. E., Roberts, T. M., Golub, T., Flaherty, K. T., Dummer, R., Weber, B. L., Sellers, W. R., Schlegel, R., Wargo, J. A., Hahn, W. C. and Garraway, L. A. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972.
14. Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T., Kominami, E., Ohsumi, Y. and Yoshimori, T. (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19, 5720-5728.
15. Karbowniczek, M., Cash, T., Cheung, M., Robertson, G. P., Astrinidis, A. and Henske, E. P. (2004) Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J. Biol. Chem. 279, 29930-29937.
16. Kim, Y.-K., Ahn, S. K. and Lee, M. (2012) Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152. Cancer Lett. 320, 215-224.
17. Ma, X., Piao, S., Wang, D. W., McAfee, Q. W., Nathanson, K. L., Lum, J. J., Li, L. Z. and Amaravadi, R. K. (2011) Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. Clin. Cancer Res. 17, 3478-3489.
18. Maddodi, N., Huang, W., Havighurst, T., Kim, K., Longley, B. J. and Setaluri, V. (2010) Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF. J. Invest. Dermatol. 130, 1657-1667.
19. Marcus, A. I., Peters, U., Thomas, S. L., Garrett, S., Zelnak, A., Kapoor, T. M. and Giannakakou, P. (2005) Mitotic kinesin inhibitors induce mitotic arrest and cell death in taxol-resistant and -sensitive cancer cells. J. Biol. Chem. 280, 11569-11577.
20. McCubrey J.A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W., Chang, F., Lehmann, B., Terrian, D. M., Milella, M., Tafuri, A., Stivala, F., Libra, M., Basecke, J., Evangelisti, C., Martielli, A. M. and Franklin, R. A. (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biocheim. Biophys. Acta 1773, 1263-1284.
21. Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M. K., Attar, N., Sazegar, H., Chodon, T., Nelson, S. F., McArthur, G., Sosman, J. A., Ribas, A. and Lo, R. S. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977.
22. Ng, G. and Huang, J. (2005) The significance of autophagy in cancer. Mol. Carcinog. 43, 183-187.
23. Nobili, S., Landini, I., Giglioni, B. and Mini, E. (2006) Pharmacological strategies for overcoming multidrug resistance. Curr. Drug Targets 7, 861-879.
24. Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G. and Varmus, H. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73.
25. Pattingre, S., Bauvy, C. and Codogno, P. (2003) Amino acids interfere with the ERK1/2-dependent control of macroautophagy by controlling the activation of Raf-1 in human colon cancer HT-29 cells. J. Biol. Chem. 278, 16667-16674.
26. Petiot, A., Ogier-Denis, E., Blommaart, E. F., Meijer, A. J. and Codogno, P. (2000) Distinct classes of phosphatidylinositol 3'-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. J. Biol. Chem. 275, 992-998.
27. Seglen, P. O. and Gordon, P. B. (1982) 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc. Natl. Acad. Sci. U.S.A. 79, 1889-1992.
28. Shintani, T., Yamazaki, F., Katoh, T., Umekawa, M., Matahira, Y., Hori, S., Kakizuka, A., Totani, K., Yamamoto, K. and Ashida, H. (2010) Glucosamine induces autophagy via an mTOR-independent pathway. Biochem. Biophys. Res. Commun. 391, 1775-1779.
29. Su, F., Bradley, W. D., Wang, Q., Yang, H., Xu, L., Higgins, B., Kolinsky, K., Packman, K., Kim, M. J., Trunzer, K., Lee, R. J., Schostack, K., Carter, J., Albert, T., Germer, S., Rosinski, J., Martin, M., Simcox, M. E., Lestini, B., Heimbrook, D. and Bollag, G. (2012) Resistance to selective braf inhibition can be mediated by modest upstream pathway activation. Cancer Res. 72, 969-978.
30. Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., Sproesser, K., Li, L., Smalley, K. S., Fong, D., Zhu, Y. L., Marimuthu, A., Nguyen, H., Lam, B., Liu, J., Cheung, I., Rice, J., Suzuki, Y., Luu, C., Settachatgul, C., Shellooe, R., Cantwell, J., Kim, S. H., Schlessinger, J., Zhang, K. Y., West, B. L., Powell, B., Habets, G., Zhang, C., Ibrahim, P. N., Hirth, P., Artis, D. R., Herlyn, M. and Bollag, G. (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. U.S.A. 105, 3041-3046.
31. Ullman, E., Fan, Y., Stawowczyk, M., Chen, H. M., Yue, Z. and Zong, W. X. (2008) Autophagy promotes necrosis in apoptosis-deficient cells in response to ER stress. Cell Death Differ. 15, 422-425.
32. Williams, A., Sarkar, S., Cuddon, P., Ttofi, E. K., Saiki, S., Siddiqi, F. H., Jahreiss, L., Fleming, A., Pask, D., Goldsmith, P., O'Kane, C. J., Floto, R. A. and Rubinsztein, D. C. (2008) Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat. Chem. Biol. 4, 295-305.
33. Wu, C. P., Calcagno, A. M. and Ambudkar, S. V. (2008) Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr. Mol. Pharmacol. 1, 93-105.
34. Wu, Y. T., Tan, H. L., Shui, G., Bauvy, C., Huang, Q., Wenk, M. R., Ong, C. N., Codogno, P. and Shen, H. M. (2010) Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J. Biol. Chem. 285, 10850-10861.